World Hypopara Awareness Day is June 1!
Join us in raising awareness for people living with hypoparathyroidism and share this link.

Advancing peptides for the treatment of rare endocrine and related diseases

We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.

PROGRAMS

AZP-3601

Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.

AZP-3813

AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development as a potential treatment for acromegaly.

AZP-3813 Acromegal

LEADERSHIP

Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.

Press Releases & Recent News

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer

Download a PDF copy of this press release: EN FR Industry veteran brings over two decades of global experience in …

Read More →
Download a PDF: EN or FR

Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

Download a PDF copy of this press release: EN FR Four abstracts accepted as poster presentations for the Endocrine Society’s …

Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top